Beyond traditional pharmacology: New tools and approaches

British Journal of Pharmacology

Volumn 172, Issue 13, 2015, Pages 3229-3241

  Gurevich, E V ^a   Gurevich, V V ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; RECOMBINANT ANTIBODY; RECOMBINANT HORMONE;

CELL DIVISION; CELL SELF REPLICATION; CELL THERAPY; GENETIC ENGINEERING; GENOME EDITING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; BIOLOGICAL THERAPY; GENE THERAPY; PHARMACOLOGY; PROCEDURES;

ANIMALS; BIOLOGICAL PRODUCTS; CELL- AND TISSUE-BASED THERAPY; GENETIC THERAPY; HUMANS; PHARMACOLOGY; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION;

EID: 84937410347     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13066     Document Type: Review

References (133)

1. Ahmed MR, Berthet A, Bychkov E, Porras G, Li Q, Bioulac BH, et al. (2010). Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med 2: 28ra28.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Ambasudhan R, Dolatabadi N, Nutter A, Masliah E, McKercher SR, Lipton SA, (2014). Potential for cell therapy in Parkinson's disease using genetically programmed human embryonic stem cell-derived neural progenitor cells. J Comp Neurol 522: 2845-2856.
5. Asokan A, Samulski RJ, (2013). An emerging adeno-associated viral vector pipeline for cardiac gene therapy. Hum Gene Ther 24: 906-913.
6. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
7. Barker RA, Barrett J, Mason S, Björklund A, (2013). Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol 12: 84-91.
8. Bartel MA, Weinstein JR, Schaffer DV, (2012a). Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther 19: 694-700.
9. Bartel MA, Weinstein JR, Schaffer DV, (2012b). Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther 19: 694-700.
10. Bartus RT, Baumann TL, Brown L, Kruegel BR, Ostrove JM, Herzog CD, (2013). Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating 'clinical proof-of-concept' for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiol Aging 34: 35-61.
11. Berman DM, Gilman AG, (1998). Mammalian RGS proteins: barbarians at the gate. J Biol Chem 273: 1269-1272.
12. Bibikova M, Beumer K, Trautman JK, Carroll D, (2003). Enhancing gene targeting with designed zinc finger nucleases. Science 300: 764.
13. Boado RJ, Hui EK, Lu JZ, Pardridge WM, (2010a). Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther 333: 961-969.
14. Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM, (2010b). Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J Biotechnol 146: 84-91.
15. Bourdenx M, Dutheil N, Bezard E, Dehay B, (2014). Systemic gene delivery to the central nervous system using Adeno-associated virus. Front Mol Neurosci 7: 50.
16. Burnett JC, Rossi JJ, Tiemann K, (2011). Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6: 1130-1146.
17. Buttery PC, Barker RA, (2014). Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? J Comp Neurol 522: 2802-2816.
18. Carman CV, Benovic JL, (1998). G-protein-coupled receptors: turn-ons and turn-offs. Curr Opin Neurobiol 8: 335-344.
19. Castanotto D, Rossi JJ, (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433.
20. Cho SW, Kim S, Kim JM, Kim JS, (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31: 230-232.
21. Christie MJ, (2008). Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 154: 384-396.
22. Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, et al. (2008). Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 105: 15112-15117.
23. Cohen P, Alessi DR, (2013). Kinase drug discovery-what's next in the field? ACS Chem Biol 8: 96-104.
24. Colella P, Auricchio A, (2012). Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients. Hum Gene Ther 23: 796-807.
25. Dacher M, Nugent FS, (2011). Opiates and plasticity. Neuropharmacology 61: 1088-1096.
26. Day TP, Byrne LC, Schaffer DV, Flannery JG, (2014). Advances in AAV vector development for gene therapy in the retina. Adv Exp Med Biol 801: 687-693.
27. Dell'Anno MT, Caiazzo M, Leo D, Dvoretskova E, Medrihan L, Colasante G, et al. (2014). Remote control of induced dopaminergic neurons in Parkinsonian rats. J Clin Invest 124: 3215-3229.
28. Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, et al. (2014). Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 538: 217-227.
29. Dessauer CW, Posner BA, Gilman AG, (1996). Visualizing signal transduction: receptors, G-proteins, and adenylate cyclases. Clin Sci (Lond) 91: 527-537.
30. DeWire SM, Violin JD, (2011). Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res 109: 205-216.
31. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK, (2007). Beta-arrestins and cell signaling. Annu Rev Physiol 69: 483-510.
32. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
33. Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN, et al. (2014). Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 115: 488-492.
34. Eglen R, Reisine T, (2011). Drug discovery and the human kinome: recent trends. Pharmacol Ther 130: 144-156.
35. Ellis BL, Hirsch ML, Porter SN, Samulski RJ, Porteus MH, (2013). Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs. Gene Ther 20: 35-42.
36. Elowitz M, Lim WA, (2010). Build life to understand it. Nature 468: 889-890.
37. Esteves AR, Swerdlow RH, Cardoso SM, (2014). LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp Neurol 261: 206-216.
38. Ezan E, (2013). Pharmacokinetic studies of protein drugs: past, present and future. Adv Drug Deliv Rev 65: 1065-1073.
39. Ezan E, Becher F, Fenaille F, (2014). Assessment of the metabolism of therapeutic proteins and antibodies. Expert Opin Drug Metab Toxicol 10: 1079-1091.
40. Fang Z, Grütter C, Rauh D, (2013). Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. ACS Chem Biol 8: 58-70.
41. Filareto A, Parker S, Darabi R, Borges L, Iacovino M, Schaaf T, et al. (2013). An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat Commun 4: 1549.
42. Fischbach MA, Bluestone JA, Lim WA, (2013). Cell-based therapeutics: the next pillar of medicine. Sci Transl Med 5: 179ps177.
43. Gelfand Y, Kaplitt MG, (2013). Gene therapy for psychiatric disorders. World Neurosurg 80: e11-e18.
44. Gherardini L, Bardi G, Gennaro M, Pizzorusso T, (2014). Novel siRNA delivery strategy: a new 'strand' in CNS translational medicine? Cell Mol Life Sci 71: 1-20.
45. Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, Kim KW, et al. (2007). RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci 27: 14338-14348.
46. Gray SJ, (2013). Gene therapy and neurodevelopmental disorders. Neuropharmacology 68: 136-142.
47. Gray-Keller MP, Detwiler PB, Benovic JL, Gurevich VV, (1997). Arrestin with a single amino acid substitution quenches light-activated rhodopsin in a phosphorylation independent fashion. Biochemistry 36: 7058-7063.
48. Grunberger G, (2013). The need for better insulin therapy. Diabetes Obes Metab 15 (Suppl. 1): 1-5.
49. Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, et al. (2005). Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord 11: S25-S29.
50. Gurevich EV, Gurevich VV, (2010). Dopamine receptors and the treatment of Parkinson's disease. In:, Neve K, (ed.) Dopamine Receptors. Humana Press: New York, pp. 525-584.
51. Gurevich EV, Gurevich VV, (2014). Therapeutic potential of small molecules and engineered proteins. Handb Exp Pharmacol 219: 1-12.
52. Gurevich EV, Tesmer JJ, Mushegian A, Gurevich VV, (2011). G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol Ther 133: 40-69.
53. Gurevich EV, Ahmed MR, Carl YT, (2014). In vivo gene silencing by virally delivered microRNA. In:, Brambilla R, (ed.). Viral Vector Approaches in Neurobiology and Brain Diseases. Humana Press: New York, pp. 245-268.
54. Gurevich VV, (1998). The selectivity of visual arrestin for light-activated phosphorhodopsin is controlled by multiple nonredundant mechanisms. J Biol Chem 273: 15501-15506.
55. Gurevich VV, Gurevich EV, (2003). The new face of active receptor bound arrestin attracts new partners. Structure 11: 1037-1042.
56. Gurevich VV, Gurevich EV, (2004). The molecular acrobatics of arrestin activation. Trends Pharmacol Sci 25: 105-111.
57. Gurevich VV, Gurevich EV, (2006). The structural basis of arrestin-mediated regulation of G protein-coupled receptors. Pharmacol Ther 110: 465-502.
58. Gurevich VV, Gurevich EV, (2010). Custom-designed proteins as novel therapeutic tools? The case of arrestins. Expert Rev Mol Med 12: e13.
59. Gurevich VV, Gurevich EV, (2012). Synthetic biology with surgical precision: targeted reengineering of signaling proteins. Cell Signal 24: 1899-1908.
60. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, et al. (2007). Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318: 1920-1923.
61. Hanson SM, Francis DJ, Vishnivetskiy SA, Klug CS, Gurevich VV, (2006). Visual arrestin binding to microtubules involves a distinct conformational change. J Biol Chem 281: 9765-9772.
62. Hanson SM, Van Eps N, Francis DJ, Altenbach C, Vishnivetskiy SA, Arshavsky VY, et al. (2007). Structure and function of the visual arrestin oligomer. EMBO J 26: 1726-1736.
63. Hanson SM, Vishnivetskiy SA, Hubbell WL, Gurevich VV, (2008a). Opposing effects of inositol hexakisphosphate on rod arrestin and arrestin2 self-association. Biochemistry 47: 1070-1075.
64. Hanson SM, Dawson ES, Francis DJ, Van Eps N, Klug CS, Hubbell WL, et al. (2008b). A model for the solution structure of the rod arrestin tetramer. Structure 16: 924-934.
65. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, et al. (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19: 979-990.
66. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, et al. (2011). Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29: 731-734.
67. Holmes E, Kinross J, Gibson GR, Burcelin R, Jia W, Pettersson S, et al. (2012). Therapeutic modulation of microbiota-host metabolic interactions. Sci Transl Med 4: 137rv136.
68. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, et al. (2010). Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28: 839-847.
69. Hopkins AL, Groom CR, (2002). The druggable genome. Nat Rev Drug Discov 1: 727-730.
70. Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, et al. (2014). RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A 111: 11461-11466.
71. Imming P, Sinning C, Meyer A, (2006). Drugs, their targets, and the nature and number of drug targets. Nat Rev Drug Discov 5: 821-834.
72. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA, (2013). RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 31: 233-239.
73. Joung JK, Sander JD, (2013). TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14: 49-55.
74. Kenakin T, Christopoulos A, (2013). Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12: 205-216.
75. Kenakin T, Miller LJ, (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
76. Kenakin TP, (2010). Ligand detection in the allosteric world. J Biomol Screen 15: 119-130.
77. Kenakin TP, (2012). Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 165: 1659-1669.
78. Kim H, Kim JS, (2014). A guide to genome engineering with programmable nucleases. Nat Rev Genet 15: 321-334.
79. Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, et al. (2012). The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 14: 112-120.
80. Kwon I, Schaffer DV, (2008). Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res 25: 489-499.
81. Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SG, Caron MG, et al. (1999). The 2-adrenergic receptor/arrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A 96: 3712-3717.
82. Lee VM, Trojanowski JQ, (2006). Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52: 33-38.
83. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, et al. (2011). In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475: 217-221.
84. Lim KL, Dawson VL, Dawson TM, (2006). Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases? Neurobiol Aging 27: 524-529.
85. Lopes VS, Diemer T, Williams DS, (2014). Assessment of different virus-mediated approaches for retinal gene therapy of Usher 1B. Adv Exp Med Biol 801: 725-731.
86. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK, (2013). CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10: 977-979.
87. Maguire AM, Simonelli F, Pierce EA, Pugh ENJ, Mingozzi F, Bennicelli J, et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
88. Marques O, Outeiro TF, (2012). Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis 3: e350.
89. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, et al. (2010). Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 120: 1774-1785.
90. Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, et al. (2007). An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25: 778-785.
91. Moaven H, Koike Y, Jao CC, Gurevich VV, Langen R, Chen J, (2013). Visual arrestin interaction with clathrin adaptor AP-2 regulates photoreceptor survival in the vertebrate retina. Proc Natl Acad Sci U S A 110: 9463-9468.
92. Nguyen J, Szoka FC, (2012). Nucleic acid delivery: the missing pieces of the puzzle? Acc Chem Res 45: 1153-1162.
93. Nickols HH, Conn PJ, (2014). Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis 61: 55-71.
94. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368: 407-415.
95. Olsson JE, Gordon JW, Pawlyk BS, Roof D, Hayes A, Molday RS, et al. (1992). Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron 9: 815-830.
96. Pardridge WM, Boado RJ, (2012). Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 503: 269-292.
97. Park CY, Kim J, Kweon J, Son JS, Lee JS, Yoo JE, et al. (2014). Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. Proc Natl Acad Sci U S A 111: 9253-9258.
98. Parkes DG, Mace KF, Trautmann ME, (2013). Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin Drug Discov 8: 219-244.
99. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
100. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, et al. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816.
101. Perez-Pinera P, Ousterout DG, Brunger JM, Farin AM, Glass KA, Guilak F, et al. (2013). Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat Methods 10: 239-242.
102. Petrocca F, Lieberman J, (2011). Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol 29: 747-754.
103. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, et al. (2013). Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 1: 3.
104. Petrs-Silva H, Linden R, (2014). Advances in gene therapy technologies to treat retinitis pigmentosa. Clin Ophthalmol 8: 127-136.
105. Pugh EN Jr, Lamb TD, (2000). Phototransduction in vertebrate rods and cones: molecular mechanisms of amplification, recovery and light adaptation. In:, Stavenga DG, DeGrip WJ, Pugh EN Jr, (eds). Handbook of Biological Physics. Molecular Mechanisms in Visual Transduction. Elsevier: Amsterdam, pp. 183-255.
106. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152: 1173-1183.
107. Ramaswamy S, Kordower JH, (2012). Gene therapy for Huntington's disease. Neurobiol Dis 48: 243-254.
108. Rask-Andersen M, Sällman Almén MS, Schiöth HB, (2011). Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 10: 579-590.
109. Remy S, Beck H, (2006). Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 129: 18-35.
110. Samama P, Cotecchia S, Costa T, Lefkowitz RJ, (1993). A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268: 4625-4636.
111. Sander JD, Joung JK, (2014). CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32: 343-355.
112. Schmitz O, Brock B, Rungby J, (2004). Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 (Suppl. 3): S233-S238.
113. Schöneberg T, Schulz A, Biebermann H, Hermsdorf T, Römpler H, Sangkuhl K, (2004). Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther 104: 173-206.
114. Sheridan C, (2011). Gene therapy finds its niche. Nat Biotechnol 29: 121-128.
115. Smith C, Gore A, Yan W, Abalde-Atristain L, Li Z, He C, et al. (2014). Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 15: 12-13.
116. Soldner F, Laganière J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, et al. (2011). Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146: 318-331.
117. Song X, Vishnivetskiy SA, Gross OP, Emelianoff K, Mendez A, Chen J, et al. (2009). Enhanced arrestin facilitates recovery and protects rod photoreceptors deficient in rhodopsin phosphorylation. Curr Biol 19: 700-705.
118. Song X, Vishnivetskiy SA, Seo J, Chen J, Gurevich EV, Gurevich VV, (2011). Arrestin-1 expression in rods: balancing functional performance and photoreceptor health. Neuroscience 174: 37-49.
119. Song X, Seo J, Baameur F, Vishnivetskiy SA, Chen Q, Kook S, et al. (2013). Rapid degeneration of rod photoreceptors expressing self-association-deficient arrestin-1 mutant. Cell Signal 25: 2613-2624.
120. Sriram SR, Li X, Ko HS, Chung KK, Wong E, Lim KL, et al. (2005). Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet 14: 2571-2586.
121. Sun N, Zhao H, (2013). Transcription activator-like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing. Biotechnol Bioeng 110: 1811-1821.
122. Szczepek M, Brondani V, Büchel J, Serrano L, Segal DJ, Cathomen T, (2007). Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat Biotechnol 25: 786-793.
123. Tan E, Wang Q, Quiambao AB, Xu X, Qtaishat NM, Peachey NS, et al. (2001). The relationship between opsin overexpression and photoreceptor degeneration. Invest Ophthalmol Vis Sci 42: 589-600.
124. Thal DM, Yeow RY, Schoenau C, Huber J, Tesmer JJ, (2011). Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol 80: 294-303.
125. Vishnivetskiy SA, Paz CL, Schubert C, Hirsch JA, Sigler PB, Gurevich VV, (1999). How does arrestin respond to the phosphorylated state of rhodopsin? J Biol Chem 274: 11451-11454.
126. Vishnivetskiy SA, Baameur F, Findley KR, Gurevich VV, (2013a). Critical role of the central 139-loop in stability and binding selectivity of arrestin-1. J Biol Chem 288: 11741-11750.
127. Vishnivetskiy SA, Chen Q, Palazzo MC, Brooks EK, Altenbach C, Iverson TM, et al. (2013b). Engineering visual arrestin-1 with special functional characteristics. J Biol Chem 288: 11741-11750.
128. Wang D, Zhong L, Nahid MA, Gao G, (2014). The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv 11: 345-364.
129. Wang Y, Zheng CG, Jiang Y, Zhang J, Chen J, Yao C, et al. (2012). Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. Cell Res 22: 637-648.
130. Wisler JW, Xiao K, Thomsen AR, Lefkowitz RJ, (2014). Recent developments in biased agonism. Curr Opin Cell Biol 27: 18-24.
131. Yuan X, Naguib S, Wu Z, (2011). Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv 8: 521-536.
132. Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu PQ, Paschon DE, et al. (2011). Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478: 391-394.
133. Zeller SJ, Kumar P, (2011). RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. Yale J Biol Med 84: 3019-3309.